Prelude Therapeutics Incorporated (NASDAQ:PRLD) CEO Krishna Vaddi Buys 100,000 Shares

Prelude Therapeutics Incorporated (NASDAQ:PRLD) CEO Krishna Vaddi purchased 100,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 18th. The stock was bought at an average cost of $0.93 per share, with a total value of $93,000.00. Following the acquisition, the chief executive officer now owns 1,167,275 shares of the company’s stock, valued at approximately $1,085,565.75. The trade was a 9.37 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Prelude Therapeutics Stock Performance

Prelude Therapeutics stock opened at $1.30 on Friday. The company has a market capitalization of $71.55 million, a PE ratio of -0.73 and a beta of 1.49. Prelude Therapeutics Incorporated has a fifty-two week low of $0.80 and a fifty-two week high of $6.80. The firm has a 50 day moving average price of $1.21 and a 200 day moving average price of $3.17.

Prelude Therapeutics (NASDAQ:PRLD) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.43) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.05. The firm had revenue of $3.00 million during the quarter. As a group, equities research analysts forecast that Prelude Therapeutics Incorporated will post -1.81 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on PRLD. HC Wainwright reissued a “buy” rating and issued a $5.00 price objective on shares of Prelude Therapeutics in a report on Friday, November 8th. JMP Securities restated a “market outperform” rating and set a $4.00 price target (down previously from $7.00) on shares of Prelude Therapeutics in a report on Wednesday, December 11th.

Institutional Trading of Prelude Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Walleye Capital LLC grew its holdings in shares of Prelude Therapeutics by 446.2% in the third quarter. Walleye Capital LLC now owns 83,175 shares of the company’s stock valued at $172,000 after purchasing an additional 67,946 shares in the last quarter. Massachusetts Financial Services Co. MA increased its stake in shares of Prelude Therapeutics by 2.8% during the second quarter. Massachusetts Financial Services Co. MA now owns 522,375 shares of the company’s stock worth $1,990,000 after buying an additional 14,226 shares during the period. Exchange Traded Concepts LLC lifted its stake in Prelude Therapeutics by 32.2% in the third quarter. Exchange Traded Concepts LLC now owns 64,409 shares of the company’s stock worth $133,000 after acquiring an additional 15,682 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in Prelude Therapeutics by 103.2% during the 2nd quarter. Dimensional Fund Advisors LP now owns 29,074 shares of the company’s stock worth $111,000 after acquiring an additional 14,769 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. lifted its position in Prelude Therapeutics by 885.2% in the third quarter. Jacobs Levy Equity Management Inc. now owns 174,979 shares of the company’s stock valued at $362,000 after acquiring an additional 157,218 shares during the last quarter. 79.72% of the stock is currently owned by hedge funds and other institutional investors.

Prelude Therapeutics Company Profile

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.